Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism

May 26, 2010

JERUSALEM, May 26, 2010 /PRNewswire-FirstCall/ –

– Study Data Shows ORMD-0801 Resulted in Glucose and C-Peptide Reduction

Oramed Pharmaceuticals Inc. (OTCBB: ORMP.OB) (http://www.oramed.com), a
developer of alternative drug delivery systems, announced today that the
paper entitled, “Open-label study to assess the safety and pharmacodynamics
of five oral insulin formulations in healthy subjects,” authored by Dr. Roy
, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in
the Diabetes, Obesity and Metabolism (DOM) journal.

“Publication of our data in a prestigious journal such as DOM lends
further credence to the importance of oral insulin as a potential drug in the
management of diabetes. The data published on formulation optimization is an
important milestone in the development of ORMD-0801, and provides the
continued evidence of clinical safety and the foundation for the proof of
concept study for our proprietary oral drug delivery platform,” said Dr.

Miriam Kidron, Chief Officer of Oramed.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via injection.
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule currently in
Phase 2 clinical trials. Established in 2006, Oramed’s technology is based on
over 25 years of research performed by top research scientists at Jerusalem’s
Hadassah Medical Center. The Company’s corporate and R&D headquarters are
based in Jerusalem.

For more information, please visit http://www.oramed.com.

Safe Harbor Statement

Some of the statements contained in this press release are
forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of the company, or industry results, to be
materially different from any future results, performance or achievements
expressed or implied by such forward looking statements, including the risks
and uncertainties related to the progress, timing, cost, and results of
clinical trials and product development programs; difficulties or delays in
obtaining regulatory approval for our product candidates; competition from
other pharmaceutical or biotechnology companies; and the company’s ability to
obtain additional funding required to conduct its research, development and
commercialization activities. Please refer to the company’s filings with the
Securities and Exchange Commission for a comprehensive list of risk factors
that could cause actual results, performance or achievements of the company
to differ materially from those expressed or implied in such forward looking
statements. The company undertakes no obligation to update or revise any
forward-looking statements.

    Company and Investor Relation Contacts:
    Oramed Pharmaceuticals Inc.
    Tara Horn
    Office: +1-646-240-4193
    Cell:   +972-54-334-4318
    Email: tara@oramed.com

SOURCE Oramed Pharmaceuticals Inc.

Source: newswire

comments powered by Disqus